The role of serum adipocyte fatty acid-binding protein on the development of metabolic syndrome is independent of pro-inflammatory cytokines

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 22, Issue 6, 2012, Pages 525-532

  Park, S E ^a,b   Rhee, E J ^a   Lee, W Y ^a   Kim, W J ^a   Yoo, S H ^a   Bae, J C ^a   Choi, E S ^a   Park, C Y ^a   Oh, K W ^a   Park, S W ^a   Kim, S W ^a  

^a School of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

FABP4; Inflammation; Insulin resistance; Metabolic syndrome

Indexed keywords

CCL2 PROTEIN, HUMAN; CYTOKINE; FABP4 PROTEIN, HUMAN; FATTY ACID BINDING PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ADIPOSE TISSUE; ADULT; ARTICLE; BLOOD; BODY MASS; DIET RESTRICTION; FEMALE; GENETICS; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PROSPECTIVE STUDY;

ADIPOCYTES; ADIPOSE TISSUE; ADULT; BLOOD GLUCOSE; BODY MASS INDEX; CHEMOKINE CCL2; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CYTOKINES; FASTING; FATTY ACID-BINDING PROTEINS; FEMALE; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROSPECTIVE STUDIES; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84861183230     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2010.09.008     Document Type: Article

References (27)

1. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752.
2. Laaksonen D.E., Lakka H.M., Niskanen L.K., Kaplan G.A., Salonen J.T., Lakka T.A. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol 2002, 156:1070-1077.
3. Lakka H.M., Laaksonen D.E., Lakka T.A., Niskanen L.K., Kumpusalo E., Tuomilehto J., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002, 288:2709-2716.
4. Han T.S., Williams K., Sattar N., Hunt K.J., Lean M.E., Haffner S.M. Analysis of obesity and hyperinsulinemia in the development of metabolic syndrome: San Antonio Heart Study. Obes Res 2002, 10:923-931.
5. Fortuno A., Rodriguez A., Gomez-Ambrosi J., Fruhbeck G., Diez J. Adipose tissue as an endocrine organ: role of leptin and adiponectin in the pathogenesis of cardiovascular diseases. J Physiol Biochem 2003, 59:51-60.
6. Makowski L., Hotamisligil G.S. Fatty acid binding proteins - the evolutionary crossroads of inflammatory and metabolic responses. J Nutr 2004, 134:2464S-2468S.
7. Coe N.R., Bernlohr D.A. Physiological properties and functions of intracellular fatty acid-binding proteins. Biochim Biophys Acta 1998, 1391:287-306.
8. Hertzel A.V., Bernlohr D.A. The mammalian fatty acid-binding protein multigene family: molecular and genetic insights into function. Trends Endocrinol Metab 2000, 11:175-180.
9. Makowski L., Boord J.B., Maeda K., Babaev V.R., Uysal K.T., Morgan M.A., et al. Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat Med 2001, 7:699-705.
10. Boord J.B., Maeda K., Makowski L., Babaev V.R., Fazio S., Linton M.F., et al. Combined adipocyte-macrophage fatty acid-binding protein deficiency improves metabolism, atherosclerosis, and survival in apolipoprotein E-deficient mice. Circulation 2004, 110:1492-1498.
11. Tso A.W., Xu A., Sham P.C., Wat N.M., Wang Y., Fong C.H., et al. Serum adipocyte fatty acid binding protein as a new biomarker predicting the development of type 2 diabetes: a 10-year prospective study in a Chinese cohort. Diabetes Care 2007, 30:2667-2672.
12. Xu A., Tso A.W., Cheung B.M., Wang Y., Wat N.M., Fong C.H., et al. Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study. Circulation 2007, 115:1537-1543.
13. Yeung D.C., Xu A., Cheung C.W., Wat N.M., Yau M.H., Fong C.H., et al. Serum adipocyte fatty acid-binding protein levels were independently associated with carotid atherosclerosis. Arterioscler Thromb Vasc Biol 2007, 27:1796-1802.
14. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
15. Vache C., Rousset P., Gachon P., Gachon A.M., Morio B., Boulier A., et al. Bioelectrical impedance analysis measurements of total body water and extracellular water in healthy elderly subjects. Int J Obes Relat Metab Disord 1998, 22:537-543.
16. Standards of medical care in diabetes-2007. Diabetes Care 2007, 30(Suppl. 1):S4-S41.
17. Eckel R.H., Grundy S.M., Zimmet P.Z. The metabolic syndrome. Lancet 2005, 365:1415-1428.
18. Makowski L., Brittingham K.C., Reynolds J.M., Suttles J., Hotamisligil G.S. The fatty acid-binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity. Macrophage expression of aP2 impacts peroxisome proliferator-activated receptor gamma and IkappaB kinase activities. J Biol Chem 2005, 280:12888-12895.
19. Grundy S.M. Inflammation, hypertension, and the metabolic syndrome. JAMA 2003, 290:3000-3002.
20. Ridker P.M., Buring J.E., Cook N.R., Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003, 107:391-397.
21. Koh J.H., Shin Y.G., Nam S.M., Lee M.Y., Chung C.H., Shin J.Y. Serum adipocyte fatty acid-binding protein levels are associated with nonalcoholic fatty liver disease in type 2 diabetic patients. Diabetes Care 2009, 32:147-152.
22. Xu A., Wang Y., Xu J.Y., Stejskal D., Tam S., Zhang J., et al. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem 2006, 52:405-413.
23. Oram J.F., Lawn R.M. ABCA1. The gatekeeper for eliminating excess tissue cholesterol. J Lipid Res 2001, 42:1173-1179.
24. Maeda K., Cao H., Kono K., Gorgun C.Z., Furuhashi M., Uysal K.T., et al. Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. Cell Metab 2005, 1:107-119.
25. Furuhashi M., Tuncman G., Gorgun C.Z., Makowski L., Atsumi G., Vaillancourt E., et al. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature 2007, 447:959-965.
26. Stevens J., Couper D., Pankow J., Folsom A.R., Duncan B.B., Nieto F.J., et al. Sensitivity and specificity of anthropometrics for the prediction of diabetes in a biracial cohort. Obes Res 2001, 9:696-705.
27. Sattar N., Gaw A., Scherbakova O., Ford I., O'Reilly D.S., Haffner S.M., et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003, 108:414-419.